Merck KGaA announced on June 25, 2026, that it had agreed to acquire U.S. biotech firm Bio-Techne for $11.3 billion in cash, its largest deal in over a decade.
The offer of $73 per share represents an enterprise value of about $11.3 billion and a 24–36% premium to Bio-Techne's recent trading price.
Merck aims to strengthen its life sciences business by adding Bio-Techne’s research reagents, proteins, antibodies, instruments, and multiomics offerings, thus expanding its footprint in advanced biological research and cell and gene therapy.
The deal is expected to close by late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval, and will be funded through cash and new debt, with cost synergies of about €140 million targeted by year three after closing.
Sources:
Germany's Merck KGaA to buy Bio-Techne - CNBC
Germany's Merck to buy Bio-Techne for $73 per share - Investing.com
Bio-Techne to Be Acquired by Merck KGaA
Merck KGaA Agrees on $11.3 Billion Purchase of Bio-Techne
Merck to acquire Bio-Techne for $11.3B in cash deal | LinkedIn
Sidley Represents Bio-Techne in Its US$11.3 Billion Acquisition by ...
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne ...
Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life ...
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint ...
Germany's Merck to Boost Lab-Tools Business With $11 Billion Bio ...
Merck KGaA: Merck Agrees to Acquire Bio-Techne Corporation | Ad-hoc
Bio-Techne agrees to $11.3 billion buyout by Germany's Merck
Merck KGaA Is Buying Bio-Techne For $11.3 Billion - Finimize
Germany's Merck to Buy Bio-Techne in $11 Billion Deal — Update
Micron Soars, Dell Falls, Bio-Techne Drops After Merck ... - YouTube